DavidMWeinreichMD

Oncology • Thornwood, NY

Physician

Join to view full profile

Dr. Weinreich is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Weinreich's full profile

Already have an account?

Office
624 Columbus Ave
Thornwood, NY 10594
Phone+1 914-372-6111

Fax+1 914-247-0160

Education & Training

University of MarylandResidency, Surgery, 1997 - 2001
Boston University School of MedicineClass of 1997

Certifications & Licensure

CA State Medical License 2010 - 2026
NY State Medical License 2015 - 2026
MD State Medical License 2001 - 2017
VA State Medical License 2003 - 2004

Publications & Presentations

PubMed

585 citations
COLLOIDAL GOLD: A NOVEL NANOPARTICLE VECTOR FOR TUMOR DIRECTED DRUG DELIVERY
Giulio F. Paciotti, Lonnie D. Myer, David M. Weinreich, Dan V. Goia, Nicolae Pavel
Drug Delivery. 2004-05-01
387 citations
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomis...
Ahmet Sezer, Saadettin Kilickap, Mahmut Gumus, Igor Bondarenko, Mustafa Ozguroglu
Lancet. 2021-02-13
602 citations
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multi...
Claus Bachert, Joseph K. Han, Martin Desrosiers, Peter Hellings, Nikhil Amin
Lancet. 2019-11-02

Journal Articles

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
David Weinreich, MD, The New England Journal of Medicine

Abstracts/Posters

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
David M. Weinreich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
David M. Weinreich, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Regeneron's Yancopoulos Receives Columbia College's Alexander Hamilton AwardNovember 22nd, 2019